Clinical Trials

The purpose of this project is to test sleep reactivity as an independent cause of Shift Work Disorder (SWD). The primary hypothesis is that those with high sleep reactivity will show persistent SWD symptoms after experimental reduction of circadian misalignment, which will then be mitigated with CBT.

Shift work increases the risk for diabetes possibly due to the adverse metabolic effects of circadian misalignment. As shift work is not foreseen to disappear, the development of individually-targeted therapies for metabolic health in these vulnerable shift workers is urgently needed. This research will determine whether our dietary intervention can mitigate the adverse metabolic effects of circadian misalignment, which may help in the design of evidence-based dietary interventions to improve the metabolic health in shift workers.

Do you have a heart or blood vessel disease, such as peripheral artery disease? This study aims to collect data and samples from people who have a heart or blood vessel disease. This may include blood tests, ultrasound exams, and heart and lung tests. Family members and healthy people may also participate. The results may help researchers better understand PAD and other heart and blood vessel diseases. Participants must be at least 2 years old. Women who are pregnant may not take part in some study activities. This study is located in Bethesda, Maryland.

Do you or a first-degree relative have a condition that raises the risk of heart disease? This study aims to test the heart and lung function of people who have a genetic or metabolic disease that raises their risk of heart disease. Participants in this study must be between 2 and 100 years old. This study is located in Bethesda, Maryland.

Are you an adult who has PAD and difficulty walking? This study is testing whether a medicine that helps the body make more white blood cells can, along with walking exercise, improve symptoms and blood flow in people who have PAD. To participate in this study, you must be between 21 and 80 years old and have PAD. Women must not be pregnant and must use birth control or have been surgically sterilized if they still have menstrual periods. This study is located in Atlanta, Georgia.

Are you an adult who has PAD and overweight or obesity? This study aims to learn whether participating in an exercise program with a weight loss program reduces PAD signs and symptoms more than an exercise program alone. To participate, you must be between 18 and 85 years old, have PAD, and have a body mass index (BMI) greater than 28 but less than 45. Participants must also be willing to use a smartphone and attend weekly study sessions. This study is located in Evanston, Illinois; New Orleans, Louisiana; and Minneapolis, Minnesota.

Are you between 65 and 85 years old and are a patient at Stanford? This study will evaluate the effect of an electronic health record (EHR) screening tool on rates of new noninvasive testing, diagnosis, and treatment of peripheral artery disease (PAD) over a 6-month period. The EHR-based screening tool will generate a group of patients at the highest risk of having undiagnosed PAD to participate in the study. To participate in this study, you must be between 65 and 85 years old, have at least 1 year of data with the Stanford EHR, and have no prior diagnosis of PAD. This study takes place in Palo Alto, California.

Are you an adult with polycythemia vera or thrombocytosis? This study aims to find a new treatment or cure for polycythemia vera and thrombocytosis by locating genes and their changes, or mutations, that may contribute to these disorders. To participate in this study, you must have polycythemia vera with elevated hemoglobin (higher than 18 in men and 16 in women) or thrombocytosis with an elevated platelet count (higher than 450,000). This study takes place in Salt Lake City, Utah.

his trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice.

Sickle Cell Disease (SCD) impairs oxygen transport to tissue and causes endothelial injury. Thus, therapeutic interventions aim to improve both, but there is an unmet need for biomarkers to determine when intervention is necessary and evaluate the effectiveness of the chosen intervention in individual patients. This study proposes to monitor SCD and its treatment through their impact on cerebral hemodynamics, as the brain is one of the most vulnerable and consequential targets of the disease. Specifically, this study will optimize quantitative magnetic resonance imaging (MRI) and advanced optical spectroscopy techniques such as frequency-domain near-infrared and diffuse correlation spectroscopies (FDNIRS-DCS) to monitor 1) cerebral oxygen transport with measures of cerebral blood flow (CBF), cerebral oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen consumption (CMRO2) and 2) endothelial function with cerebrovascular reactivity (CVR).